CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) announced the launch of Vibativ (telavancin) injection in China through an exclusive commercialization partnership with SciClone Pharmaceuticals, following NMPA regulatory approval.

Vibativ is a once-daily, patented, FDA-approved antibiotic for serious Gram-positive infections, including MRSA-related hospital-acquired and ventilator-associated pneumonia and complicated skin and skin structure infections.

Positive

• NMPA approval enables commercial launch of Vibativ in China
• Exclusive partnership with SciClone for registration, promotion and distribution across China
• Vibativ targets serious Gram-positive infections including MRSA and MSSA
• Once-daily dosing and bactericidal activity within six hours
• Registrational studies showed higher cure rates than vancomycin in specified HABP/VABP patients

Negative

• None.

News Market Reaction – CPIX

+2.05%

2 alerts

+2.05% Session close to close

$92.14M Market Cap

0.1x Rel. Volume

In the May 28 session, CPIX gained 2.05%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement expands Vibativ® access into China through SciClone, following NMPA approval and b...

Analysis

This announcement expands Vibativ® access into China through SciClone, following NMPA approval and building on its existing approvals for HABP/VABP and cSSSI. The product offers once-daily dosing and bactericidal activity within six hours, with data showing higher cure rates vs vancomycin in certain patients. In parallel, Cumberland is pursuing a proposed $100 million Apotex asset sale and advancing ifetroban programs, so investors may watch future updates on China uptake and the transaction’s closing conditions.

Key Figures

Dosing frequency: Once-daily Bactericidal activity time: Within six hours Vancomycin MIC threshold: MIC ≥1 µg/mL +1 more

4 metrics

Dosing frequency Once-daily Telavancin regimen for severe infections

Bactericidal activity time Within six hours In vitro bactericidal activity of telavancin

Vancomycin MIC threshold MIC ≥1 µg/mL Higher cure rates vs vancomycin in HABP/VABP subgroup

Healthy China initiative year 2030 SciClone reference to 'Healthy China 2030' initiative

Historical Context

5 past events · Latest: May 05 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 05	Q1 2026 earnings	Negative	-4.0%	Reported Q1 2026 net loss alongside strategic $100M Apotex transaction.
Apr 30	Clinical candidate data	Positive	-0.5%	Partner RedHill announced encouraging RHB-204 in vitro efficacy data.
Apr 28	Earnings call notice	Neutral	-1.6%	Scheduled Q1 2026 results call and highlighted pipeline and branded portfolio.
Apr 27	Partner earnings	Positive	+3.2%	RedHill reported 2025 results and strategic/licensing milestones involving Cumberland.
Apr 23	Apotex asset sale	Positive	+27.9%	Announced $100M cash sale of U.S. branded portfolio to Apotex affiliate.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent CPIX-specific news, including a major asset sale, generally saw aligned price moves, while at least one partner-related item showed a mild divergence.

Recent Company History

Over the past months, Cumberland reported Q1 2026 results with net revenues of $9.1 million and a net loss of $3.3 million, alongside a transformative $100 million asset sale to an Apotex affiliate. Earlier news detailed the planned Q1 release and ongoing ifetroban Phase II programs. Related partner headlines highlighted RedHill’s financials and RHB-204 development progress. The current China launch for Vibativ® extends the brand’s geographic reach while prior filings tied Vibativ to potential contingent milestone and inventory arrangements in the Apotex transaction.

Key Terms

antimicrobial resistance, hospital-acquired and ventilator-associated pneumonia, gram-positive bacteria, methicillin-resistant staphylococcus aureus, +4 more

8 terms

antimicrobial resistance medical

"Antimicrobial resistance continues to be a critical global health challenge..."

Antimicrobial resistance is when microbes such as bacteria, viruses or fungi evolve so that medicines meant to kill them no longer work — like a lock changing so the old key no longer fits. For investors, this increases demand and cost for new treatments, prolongs hospital stays, prompts tougher regulation and can shrink sales of once-effective drugs, affecting pharmaceutical revenues, R&D spending and broader healthcare risk.

hospital-acquired and ventilator-associated pneumonia medical

"treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)..."

Hospital-acquired pneumonia is a lung infection patients pick up during a stay in a medical facility, while ventilator-associated pneumonia is a similar infection that develops in patients using a breathing machine. Both increase treatment time, medical costs and risk of complications, so they matter to investors because they can drive demand for antibiotics, diagnostic tests, infection-control products and can trigger regulatory scrutiny or higher hospital expenses—like a costly complication that lengthens and intensifies care.

gram-positive bacteria medical

"other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus..."

Gram-positive bacteria are a group of bacteria that retain a purple color in a standard lab dye test because they have a relatively thick, rigid outer wall. Investors should care because that structural difference affects how infections are detected, how antibiotics and vaccines work against them, and how biotech or pharmaceutical products are developed, regulated and monitored for safety—much like knowing whether an enemy wears chainmail changes strategy and equipment.

methicillin-resistant staphylococcus aureus medical

"including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive..."

A strain of the common bacteria Staphylococcus aureus that has evolved resistance to methicillin and many standard antibiotics, making infections harder to treat. Think of it like a lock that standard keys (typical antibiotics) no longer open; that raises the chance of longer hospital stays, extra treatments and higher costs. Investors care because resistant infections influence healthcare spending, drug and diagnostic demand, hospital liability and regulatory scrutiny, affecting healthcare, biotech and insurer financial outlooks.

methicillin-sensitive staphylococcus aureus medical

"including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive..."

A strain of Staphylococcus aureus bacteria that is still treatable with methicillin and related antibiotics, often causing skin, wound, bloodstream and surgical-site infections. For investors, changes in how common or easy it is to treat this infection affect demand for antibiotics, hospital spending, clinical trial results and regulatory decisions—much like a widespread product flaw would influence manufacturing costs and market demand.

lipoglycopeptide medical

"It is a once-daily, injectable lipoglycopeptide antibiotic with in vitro potency..."

A lipoglycopeptide is a type of antibiotic made by attaching a fat-like tail to a sugar-and-peptide core, which helps the drug bind to and break bacterial cell walls, often working against hard-to-treat, resistant infections. Investors watch this drug class because successful clinical results and regulatory approval can create a valuable treatment with strong demand, similar to a new tool that finally reaches and disarms a stubborn lock that other keys couldn’t open.

in vitro medical

"with in vitro potency, bactericidal activity within six hours..."

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

in vivo medical

"well-documented evidence of the drug's in vitro potency and in vivo activity..."

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Commercialization in China through partnership with SciClone Pharmaceuticals

Expands access to potentially life-saving antibiotic in the world's second-largest pharmaceutical market

NASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ^® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited.

The launch follows a previously announced agreement granting SciClone exclusive rights to register, promote and distribute telavancin, injection across China. The product's approval by China's National Medical Products Administration (NMPA) enables SciClone to commercialize the product in one of the world's largest and fastest-growing pharmaceutical markets.

Telavancin is a patented, FDA-approved injectable anti-infective that serves as a potentially life-saving treatment for patients with serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. The therapy is designed to treat infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

"Launching telavancin in China marks a significant milestone in advancing our mission of providing unique products that improve the quality of patient care," said A.J. Kazimi, Cumberland Pharmaceuticals CEO. "Through our partnership with SciClone, we are expanding access to this important therapy and providing physicians in China with a valuable new option to treat serious, difficult-to-manage infections."

Antimicrobial resistance continues to be a critical global health challenge, reducing the effectiveness of many existing antibiotics and increasing the need for innovative treatments. Telavancin was specifically designed to address resistant pathogens, offering potent activity against difficult-to-treat infections.

Mr. Zhao Hong, President and Chief Executive Officer of SciClone Pharmaceuticals, stated, "The successful launch of telavancin for injection in China represents another important milestone for SciClone Pharmaceuticals in the anti-infective field. Currently, MRSA remains a serious challenge and poses a significant clinical threat, particularly in respiratory tract infections, especially those that are hospital-acquired. With its unique dual bactericidal mechanism, broad antibacterial spectrum, and once-daily dosing regimen, telavancin offers an important new anti-infective option for Chinese patients with severe infections, delivering both improved efficacy and clinical convenience. Looking ahead, SciClone Pharmaceuticals will continue to focus on severe infection and oncology, address unmet medical needs, and accelerate the launch of more innovative products in China to contribute to the 'Healthy China 2030' initiative."

About Vibativ^®

Vibativ^® (telavancin) injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA. It is a once-daily, injectable lipoglycopeptide antibiotic with in vitro potency, bactericidal activity within six hours and penetration into target infection sites. The drug is approved in the U.S. and Saudi Arabia for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of S. aureus when alternative treatments are not suitable.

In addition, telavancin is approved in the U.S. and Saudi Arabia for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including S. aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains. The product labeling also describes the use of telavancin in treating patients whose pneumonia or skin infection is complicated by concurrent bacteremia. The product's proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients with S. aureus infections studied to date. Importantly, these studies demonstrated significantly higher cure rates for telavancin as compared to vancomycin in HABP/VABP due to any single Gram-positive pathogen or S. aureus with vancomycin MIC ≥1 µg/mL. Additionally, there is extensive and well-documented evidence of the drug's in vitro potency and in vivo activity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

For full prescribing information, including important safety information, visit www.vibativ.com.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals") is a global biopharmaceutical company with an integrated platform for the development and commercialization of innovative therapies for cancer and severe infection.

With an innovation-driven strategic transformation, SciClone Pharmaceuticals has established a product portfolio with differentiated advantages, including a number of first-in-class and best-in-class potential products / pipelines. Staying true to its original aspiration of "SciClone gives life hope," SciClone Pharmaceuticals is dedicated to improving patients' health by providing top-tier health care products and services with global standards of care.

For more information regarding SciClone Pharmaceuticals, please visit: www.sciclone.com.

For SciClone press contacts please reach out to pr@sciclone.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late stage product candidates across multiple therapeutic areas with significant unmet medical needs.

For more information, please visit www.cumberlandpharma.com.

FORWARD LOOKING STATEMENTS:

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "goal", "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include risks and uncertainties related to the strategic transaction, risks related to our ability to develop our pipeline of new product candidates, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the Company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

 

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-launch-of-vibativ-in-china-302784350.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

What did Cumberland Pharmaceuticals (CPIX) announce about Vibativ in China on May 28, 2026?

Cumberland announced the commercial launch of Vibativ (telavancin) injection in China through a partnership with SciClone, following NMPA approval. According to Cumberland, SciClone receives exclusive rights to register, promote and distribute Vibativ across the Chinese market.

How does the SciClone partnership affect Cumberland Pharmaceuticals (CPIX) and Vibativ in China?

The partnership grants SciClone exclusive rights to register, promote and distribute Vibativ across China. According to the companies, this collaboration enables commercialization in one of the world’s largest pharmaceutical markets and expands patient access to telavancin for severe Gram-positive infections.

What infections is Vibativ (telavancin) designed to treat for Cumberland Pharmaceuticals (CPIX) patients?

Vibativ is designed to treat serious Gram-positive infections, including MRSA and MSSA. According to Cumberland, indications include hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections in adults, including cases complicated by concurrent bacteremia.

What clinical advantages of Vibativ (telavancin) does Cumberland Pharmaceuticals (CPIX) highlight?

Cumberland highlights once-daily dosing, in vitro potency, bactericidal activity within six hours and good tissue penetration. According to Cumberland, registrational studies showed significantly higher cure rates versus vancomycin in HABP/VABP due to single Gram-positive pathogens or S. aureus with vancomycin MIC ≥1 µg/mL.

Why is launching Vibativ (telavancin) in China important for Cumberland Pharmaceuticals (CPIX)?

The launch provides a new treatment option for severe Gram-positive infections in China. According to Cumberland, commercialization with SciClone expands access to telavancin amid rising antimicrobial resistance, aligning with SciClone’s focus on severe infections and China’s “Healthy China 2030” healthcare goals.